Abstract:Background: Profiling of targetable oncogenic drivers has significantly improved outcomes in patients with nonesmall cell lung cancer (NSCLC). About 40% of individuals with metastatic lung adenocarcinomas may benefit from personalized treatment with kinase inhibitors. There is limited data of the distribution of oncogenic drivers other than ALK and EGFR in our region. In this study we performed next generation sequence (NGS) to study the distribution of molecular alterations in patients with advanced lung canc… Show more
“…This could be attributed to the scarcity of thoracic oncology surgeons in the country 15 . Results from a retrospective cohort study in Brazil in patients with stage IIIB NSCLC showed that 30.4% of patients received cCRT and 8.7% patients received sCRT as part of initial therapy 24 . Another study (IIIA 20.9%, IIIB 22.4%) showed that only about one‐fourth of patients (24.6%) received curative surgery 25 that could be attributed to the unequal distribution of thoracic surgeons in the country 26 .…”
Section: Discussionmentioning
confidence: 99%
“… 15 Results from a retrospective cohort study in Brazil in patients with stage IIIB NSCLC showed that 30.4% of patients received cCRT and 8.7% patients received sCRT as part of initial therapy. 24 Another study (IIIA 20.9%, IIIB 22.4%) showed that only about one‐fourth of patients (24.6%) received curative surgery 25 that could be attributed to the unequal distribution of thoracic surgeons in the country. 26 There is heterogeneity in the treatment pattern within Brazil 27 where although CRT is largely the SoC for treatment of patients with LA NSCLC, results of the retrospective analysis in elderly patients (>65 years) with unresectable LA disease has shown that about 40% of patients received best supportive care and about 30% of patients each received definitive radiotherapy alone or CRT.…”
Introduction
Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era.
Methods
The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow‐up) were collected. Summary statistics, Kaplan–Meier survival estimates and a two‐sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi‐variate analyses.
Results
A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0–89.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression‐free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1–18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, adenocarcinoma and curative surgery (p < 0.05).
Conclusion
Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.
“…This could be attributed to the scarcity of thoracic oncology surgeons in the country 15 . Results from a retrospective cohort study in Brazil in patients with stage IIIB NSCLC showed that 30.4% of patients received cCRT and 8.7% patients received sCRT as part of initial therapy 24 . Another study (IIIA 20.9%, IIIB 22.4%) showed that only about one‐fourth of patients (24.6%) received curative surgery 25 that could be attributed to the unequal distribution of thoracic surgeons in the country 26 .…”
Section: Discussionmentioning
confidence: 99%
“… 15 Results from a retrospective cohort study in Brazil in patients with stage IIIB NSCLC showed that 30.4% of patients received cCRT and 8.7% patients received sCRT as part of initial therapy. 24 Another study (IIIA 20.9%, IIIB 22.4%) showed that only about one‐fourth of patients (24.6%) received curative surgery 25 that could be attributed to the unequal distribution of thoracic surgeons in the country. 26 There is heterogeneity in the treatment pattern within Brazil 27 where although CRT is largely the SoC for treatment of patients with LA NSCLC, results of the retrospective analysis in elderly patients (>65 years) with unresectable LA disease has shown that about 40% of patients received best supportive care and about 30% of patients each received definitive radiotherapy alone or CRT.…”
Introduction
Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre‐immuno‐oncology era.
Methods
The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow‐up) were collected. Summary statistics, Kaplan–Meier survival estimates and a two‐sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi‐variate analyses.
Results
A total of 231 patients was enrolled, the median age was 65.0 years (range 21.0–89.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (>25) were used; chemotherapy alone was the most common (24.8%). The overall median progression‐free survival (mPFS) and median overall survival (mOS) were 14.8 months (95% CI, 12.1–18.6) and 48.6 months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0/1, female gender, resectable tumours, adenocarcinoma and curative surgery (p < 0.05).
Conclusion
Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.